Claims for Patent: 9,133,461

Summary for Patent: 9,133,461

Title:	Compositions and methods for inhibiting expression of the ALAS1 gene
Abstract:	The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1.
Inventor(s):	Bettencourt; Brian (Groton, MA), Fitzgerald; Kevin (Brookline, MA), Querbes; William (Cambridge, MA), Desnick; Robert J. (New York, NY), Yasuda; Makiko (New York, NY)
Assignee:	Alnylam Pharmaceuticals, Inc. (Cambridge, MA) Icahn School of Medicine at Mount Sinai (New York, NY)
Application Number:	13/835,613
Patent Claims:	1. A double-stranded ribonucleic acid (dsRNA) for inhibiting expression of ALAS1, wherein said dsRNA comprises a sense strand and an antisense strand, wherein: (i) the antisense strand is complementary to at least nucleotides 871-889 of SEQ ID NO:1 and comprises SEQ ID NO:1296, (ii) the sense strand comprises at least 15 contiguous nucleotides from SEQ ID NO:1295, (iii) a ligand and linker with a structure as shown below is attached to the 3' end of the sense strand of the dsRNA ##STR00028## and (iv) the dsRNA comprises one or more nucleotides with a modification chosen from a 2'-O-methyl modified nucleotide, a 2'-fluoro modified nucleotide, or both. 2. A double-stranded ribonucleic acid (dsRNA) for inhibiting expression of ALAS1, comprising: (i) an antisense strand complementary to at least nucleotides 871-889 of SEQ ID NO:1; (ii) a sense strand comprising at least 15 contiguous nucleotides from SEQ ID NO:1295; (iii) one or more N-acetylgalactosamine (GalNAc) derivatives; and (iv) one or more nucleotides with a modification chosen from a 2'-O-methyl modified nucleotide, a 2'-fluoro modified nucleotide, or both. 3. The dsRNA of claim 2, wherein the antisense strand comprises the sequence of SEQ ID NO:1296. 4. The dsRNA of claim 3, wherein the sense strand comprises the sequence of SEQ ID NO:1295. 5. The dsRNA of claim 3, wherein the dsRNA comprises at least five 2'-O-methyl modified nucleotides and at least five 2'-fluoro modified nucleotides. 6. The dsRNA of claim 5, wherein the dsRNA comprises one or more phosphorothioate linkages. 7. The dsRNA of claim 6, wherein the dsRNA comprises at least 20 modified nucleotides. 8. The dsRNA of claim 6, wherein the dsRNA comprises nucleotide modifications over the entire length of the sense and antisense strands. 9. The dsRNA of claim 3, which comprises at least one blunt-end. 10. The dsRNA of claim 3, wherein both ends of the dsRNA are blunt-ended. 11. The dsRNA of claim 3, wherein at least one strand comprises a 3' overhang of at least 1 nucleotide. 12. The dsRNA of claim 11, wherein the 3' overhang is 2 nucleotides in length. 13. The dsRNA of claim 11, wherein the 3' overhang is present on the 3' end of either the antisense strand or the sense strand, or both 3' ends of the antisense strand and the sense strand of the dsRNA. 14. The dsRNA of claim 11, wherein the 3' overhang is in the antisense strand. 15. The dsRNA of claim 14, wherein one or more of the nucleotides in the overhang is a nucleoside thiophosphate. 16. The dsRNA of claim 3, comprising a duplex region of 15-30 base pairs in length. 17. The dsRNA of claim 16, wherein the duplex region is 19 to 23 nucleotides in length. 18. The dsRNA of claim 3, wherein each strand is no more than 30 nucleotides in length. 19. The dsRNA of claim 18, wherein each of the sense strand and the antisense strand are 15-30 nucleotides in length. 20. The dsRNA of claim 19, wherein each strand is 19 to 24 nucleotides in length. 21. The dsRNA of claim 3, wherein the one or more GalNAc derivatives is attached to the 3' end of the sense strand. 22. The dsRNA of 3, wherein the one or more GalNAc derivatives is a biantennary or a triantennary GalNAc ligand. 23. The dsRNA of 22, wherein the GalNAc ligand is: ##STR00029## 24. The dsRNA of 23, wherein the GalNAc ligand is attached to the 3' end of the sense strand. 25. The dsRNA of 23, wherein the GalNAc ligand is attached to the 3' end of the sense strand via linker. 26. The dsRNA of 22, wherein GalNAc ligand and linker have the structure of: ##STR00030## 27. The dsRNA of claim 26, wherein the dsRNA inhibits the expression of ALAS1 mRNA by at least 50%. 28. The dsRNA of claim 3, wherein the antisense strand is fully complementary to at least nucleotides 871-889 of SEQ ID NO:1. 29. A double-stranded ribonucleic acid (dsRNA) for inhibiting expression of ALAS1, comprising: (i) an antisense strand that comprises the sequence of SEQ ID NO:1296; (ii) a sense strand comprising at least 15 contiguous nucleotides from SEQ ID NO:1295; (iii) a duplex region of 15-30 base pairs in length; (iv) a biantennary or a triantennary GalNAc ligand; (v) 20 or more modified nucleotides chosen from 2'-O-methyl modified nucleotides and 2'-fluoro modified nucleotides; and (vi) at least one strand comprising a 3' overhang of at least 1 nucleotide. 30. The dsRNA of claim 29, wherein each of the sense strand and the antisense strand are 19-24 nucleotides in length. 31. The dsRNA of claim 30, wherein the antisense strand comprises the 3'-overhang. 32. The dsRNA of claim 31, wherein the 3'-overhang is 2 nucleotides in length. 33. The dsRNA of claim 32, which comprises a blunt-ended sense strand. 34. The dsRNA of claim 33, wherein the dsRNA comprises one or more phosphorothioate linkages. 35. The dsRNA of claim 34, comprising 2'-O-methyl modified nucleotides and 2'-fluoro modified nucleotides over the entire length of the sense and antisense strands. 36. The dsRNA of 33, wherein the GalNAc ligand is: ##STR00031## 37. The dsRNA of 36, wherein the GalNAc ligand is attached to the 3' end of the sense strand. 38. The dsRNA of 36, wherein the GalNAc ligand is attached to the 3' end of the sense strand via linker. 39. The dsRNA of 38, wherein GalNAc ligand and linker have the structure of: ##STR00032## 40. A double-stranded ribonucleic acid (dsRNA) for inhibiting expression of ALAS1, comprising: (i) an antisense strand that is fully complementary to at least nucleotides 871-889 of SEQ ID NO:1; (ii) a sense strand comprising at least 15 contiguous nucleotides from SEQ ID NO:1295, wherein each of the sense strand and the antisense strand are 19-24 nucleotides in length; (iii) a ligand attached to the 3' end of the sense strand and having the structure: ##STR00033## (iv) modified nucleotides over the entire length of the sense strand and the antisense strand consisting of 2'-O-methyl modified nucleotides, 2'-fluoro modified nucleotides, and phosphorothioate linkages; (v) the antisense strand comprising a 3'-overhang of 2 nucleotides in length; and (vi) a blunt-ended sense strand. 41. A pharmaceutical composition comprising the dsRNA of claim 3. 42. A pharmaceutical composition comprising the dsRNA of claim 29. 43. A pharmaceutical composition comprising the dsRNA of claim 40. 44. The pharmaceutical composition of claim 42, further comprising an unbuffered solution. 45. The pharmaceutical composition of claim 42, wherein said pharmaceutical composition is formulated for intravenous or subcutaneous administration. 46. An isolated cell containing the dsRNA of claim 3. 47. The cell of claim 46, which is a liver cell. 48. A method of treating a disorder related to ALAS1 expression comprising administering to a subject in need of such treatment the dsRNA of claim 29. 49. The method of claim 48, wherein the subject is at risk for developing, or is diagnosed with, a porphyria. 50. The method of claim 49, wherein the method decreases a level of a porphyrin or a porphyrin precursor in the subject. 51. The method of claim 49, wherein the method decreases the frequency of acute attacks of symptoms associated with the porphyria. 52. The method of claim 49, wherein the method decreases incidence of acute attacks of symptoms associated with a porphyria in the subject when the subject is exposed to a precipitating factor. 53. The method of claim 49, wherein the porphyria is a hepatic porphyria selected from the group consisting of acute intermittent porphyria (AIP), hereditary coproporphyria (HCP), variegate porphyria (VP), ALA deyhdratase deficiency porphyria (ADP), and hepatoerythropoietic porphyria. 54. The method of claim 49, wherein the dsRNA or composition comprising the dsRNA is administered before, during, or after an acute attack of porphyria. 55. The method of claim 49, wherein the dsRNA or composition comprising the dsRNA is administered during a prodrome. 56. The method of claim 49, wherein the subject has an elevated level of ALA, PBG, or both ALA and PBG. 57. A method of treating a subject with an elevated level of ALA, PBG or both ALA and PBG, the method comprising administering to the subject the dsRNA of claim 29. 58. A method of treating a porphyria comprising administering to a subject in need of such treatment the dsRNA of claim 40.